HEPA

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Edison, New Jersey, dedicated to developing innovative therapies for chronic liver diseases, with a particular focus on non-alcoholic steatohepatitis (NASH). The company is anchored by a strong pipeline and advanced drug discovery and development platforms that aim to meet significant unmet medical needs in hepatology. Its lead candidate, CRV431, shows substantial potential in treating liver conditions, positioning Hepion as a key player in the burgeoning market for liver therapeutics and highlighting its commitment to enhancing patient outcomes in this underserved space.